2023 OTS Lifetime Achievement Award Winner Cy A. Stein, MD, PhD
Cy A. Stein, MD, PhD Cy A. Stein, MD, PhD was born in New York City. He received a BA degree from Brown University (1974) and a PhD in chemistry from Stanford (1978) under Henry Taube (Nobel Laureate, 1983). A career change took him ...
2022 OTS Lifetime Achievement Award Winner Sudhir Agrawal, D.Phil.
Sudhir Agrawal, D.Phil.Founder and President, Arnay SciencesDr. Agrawal is the founder and President of Arnay Sciences, a life science research company pursuing RNA therapeutics. Dr. Agrawal started his work on antisense in the late eighties in the laboratory of Paul Zamecnik, a pioneer of antisense ...
Follow-up Data Confirms That Inclisiran Provides Long-Term Reduction of LDL-Cholesterol
Cardiovascular disease is the leading cause of death in the United States, exceeding all types of cancer, unintentional injury, and stroke combined. However, updated data from Novartis's open-label trial shows promising long-term results for inclisiran (Leqvio), the first and only small interfering RNA (siRNA) ...
Meet OTS’ New BOD Trainee Reps
Time: 8AM PST | 11AM EST | 5PM CET Date: February 22, 2024 Title: Advancing Therapeutic Approaches for Erythropoietic Protoporphyria Description: Currently, no curative treatment is available for the rare disease erythropoietic protoporphyria (EPP). The genetic background of EPP is well ...
The First FDA Approval for a GalNAc-conjugated ASO
It starts with a pins-and-needle sensation in your feet, or maybe your gastrointestinal tract has become easily irritated, or you've started to lose weight or develop heart problems. Hereditary ATTR amyloidosis can present differently among patients and with symptoms found in far more common ...
Base Editing in Clinical Trials to Treat Acute Lymphoblastic Leukemia
Base editing has experienced a rapid rise in use since it first came on the scene in 2016, with multiple trials underway, testing its ability to treat conditions with precise, single-letter changes to DNA. The technique presents a potentially more accurate and safer method ...
Interview with Roberto El-Khoury, PhD
Roberto El-Khoury, PhD Eli Lilly and Company How did you become interested in the field? I recall being drawn to the field of oligonucleotide therapeutics in high school biology classes, but it was only years later, when I was offered the opportunity to pursue my ...
2023 Annual Meeting Poster Awardee Spotlight
Time: 8AM PST | 11AM EST | 5PM CET Date: January 25, 2024 Title: siRNA therapy for ex vivo treatment of stem cell grafts and/or donor lymphocytes Description: Allogeneic T cells represent the most potent treatment for hematopoietic malignancies such es ...
President’s Pick Article – December 2023
The OTS Annual Meeting 2023 in Barcelona was a showcase of excellent science and a demonstration of how far our field has advanced over the past nineteen years. Congratulations to our LAA winners Dr. Sudhir Agrawal and Dr. Cy Stein, our other award winners, our ...
